Intellia Therapeutics Q2 collaboration revenue falls, net loss widens

INTELLIA THERAPEUTICS

06/08/2026 12:20

Overview
U.S. gene editing firm's Q2 collaboration revenue fell yr/yr due to lower Regeneron revenue
Q2 net loss widened from prior year
Company highlighted positive Phase 3 lonvo-z data and resumed key Phase 3 trial enrollment

Outlook
Intellia expects FDA acceptance of lonvo-z BLA in H2 2026 and U.S. launch in H1 2027
Company expects MAGNITUDE-2 enrollment for nex-z in ATTRv-PN to complete in H2 2026
Intellia expects cash resources to fund operations at least into 2028

Result Drivers
REGNERON REVENUE DECLINE - Co said lower collaboration revenue was primarily due to reduced payments from Regeneron
R&D COSTS DOWN - Co attributed lower R&D expenses to reduced external costs for lead programs and lower stock-based compensation, partially offset by higher employee-related expenses
COMMERCIAL BUILDOUT - Co said higher G&A expenses were driven by commercial infrastructure buildout, legal expenses and stock-based compensation

Company press release: ID:nGNX9Bn0Hh

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
 
$7.66 mln
 
Q2 Net Loss
 
$106.63 mln
 
Q2 Loss Per Basic Share
 
$0.80
 
Q2 Operating Expenses
 
$120.42 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for INTELLIA THERAPEUTICS, INC. is $17.00, about 55% above its August 5 closing price of $10.97

Reuters Recommended Reads
Aug 5 - Editas Medicine Q2 net loss narrows and beats estimates
Aug 3 - Switzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion
Aug 4 - Precigen posts quarterly profit as PAPZIMEOS sales surge

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)